Shots: Lilly to present results from a long-term study that evaluated the efficacy of Olumiant (4mg, qd) in patients with mod. to sev. RA for 3yrs. of treatment. The study […]readmore
Tags : Lilly
Shots: The collaboration will evaluate whether Jardiance can improve outcomes and prevent heart failure in adults with/ out diabetes who had an acute MI. The study assesses the efficacy of […]readmore
Shots: Lilly will get an exclusive license to perform clinical development, manufacturing and distribution of products outside of China while Junshi will maintain all rights in Greater China The collaboration […]readmore
Shots: Sitryx to receive $50M upfront, $10M equity investment, ~820M as development & commercial milestones and royalties on sales of therapies. Lilly to get an exclusive global license to develop […]readmore
Shots: Lilly enters into a non-exclusive commercialization agreement with DexCom to integrate Dexcom’s CGM device in both the pen- and pump-based platforms, designed to improve diabetes management The collaboration will […]readmore
Shots: The two P-III EMPERIAL-preserved & -reduced studies involve assessing the effect of 12wks. treatment of Jardiance (qd, 10mg) vs PBO in 315 & 312 patients with CHF along with […]readmore
Roche’s Kadcyla (trastuzumab emtansine) Receives CHMP’s Recommendation for Approval as an Adjuvant Treatment for Patients with HER2+ eBC with Residual Invasive Disease After Neoadjuvant Treatment Published: Nov 15, 2019 | Tags: […]readmore
Shots: The US FDA’s Endocrinologic and Metabolic Drugs Advisory Committee has voted (2 out of 14) against the use of Empagliflozin 2.5 mg as an add-on to insulin therapy in […]readmore
Shots: The P-III EMPLULSE study (NCT04157751) will evaluate clinical benefits safety and tolerability of Jardiance (empagliflozin, 10mg, PO) in ~500 patients hospitalized for acute heart failure who have been stabilized […]readmore
1. Triumvira’s TAC01-CD19 Receives FDA’s Fast Track Designation for R/R Diffuse Large B-Cell Lymphoma Published: Nov 07, 2019 | Tags: Triumvira, TAC01-CD19, Receives, FDA, Fast Track Designation, R/R, Diffuse Large B-Cell […]readmore